Hadrian Chui
Joined Patexia at Jan 26, 2016
Hadrian Chui
Mar 31, 2016
Chief executive Sir Andrew Witty said he wanted to take a "graduated" approach to the company's "intellectual property" based on the wealth of nations around the globe. GlaxoSmithKline to 'drop patents in poor countries for better drug access' - BBC News UK pharmaceutical giant GlaxoSmithKline says it wants to make... Read More
Hadrian Chui
Mar 30, 2016
NEW DELHI: The Delhi High Court has allowed the Competition Commission of India to look into complaints from Micromax and Intex that Ericsson had abused its dominant position to demand for royalties on the total handset cost, which the companies say were excessive. CCI free to probe Ericsson in patent... Read More
Hadrian Chui
Mar 30, 2016
The U.S. Supreme Court declined to hear Florida-based ParkerVision’s patent infringement lawsuit against Qualcomm, putting an end to an intellectual property dispute dating back to 2011. ParkerVision exhausts appeals in Qualcomm patent case | SanDiegoUnionTribune.com ParkerVision exhausts appeals in Qualcomm patent case
Hadrian Chui
Mar 28, 2016
OnePlus One was one of the best smartphones of 2014, and the OnePlus 2 was quite popular last year as well. This company is expected to release their third-gen flagship this year, and they’ve already confirmed that the phone will be announced before the end of second quarter this year,... Read More
Hadrian Chui
Mar 24, 2016
Akers Biosciences Inc. recently won a patent from the United States Patent and Trademark Office (USPTO) for its proprietary protein preparation. The preparation serves as the antigen and biologically active component for the Particle ImmunoFiltration (PIFA Heparin/PF4) Rapid Assay and PIFA PLUSS PF4 tests, which detect heparin-induced thrombocytopenia (HIT). Akers... Read More
Hadrian Chui
Mar 23, 2016
Big biotechs Gilead Sciences (GILD) and Biogen (BIIB) both fell Wednesday after receiving unfavorable patent news. Gilead, Biogen Down On Negative Patent Rulings | Stock News & Stock Market Analysis - IBD Big biotechs Gilead Sciences and Biogen were both trading down Wednesday morning after receiving unfavorable patent news.